Cabita 500 mg (Tablet)
Medicine Details
| Category | Details |
|---|---|
| Generic | Capecitabine |
| Company | Drug international ltd |
Title
Capecitabine 500mg Film-Coated Tablet
Categories
- Medicine
- Chemotherapy
- Antineoplastic
Description
Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumour, where it inhibits DNA synthesis and slows the growth of tumour tissue. It is indicated for adjuvant colon cancer, metastatic colorectal cancer, metastatic breast cancer, and is used in combination with docetaxel after failure of prior anthracycline-containing therapy.
Dosage
- Monotherapy: 1250 mg/m2 twice daily orally for 2 weeks followed by a one-week rest period in 3-week cycles
- Adjuvant Treatment: Recommended for a total of 6 months (8 cycles)
- In Combination with Docetaxel: 1250 mg/m2 twice daily for 2 weeks followed by a 7-day rest period, combined with docetaxel at 75 mg/m2 as a 1-hour IV infusion every 3 weeks
Interaction
- Anticoagulants monitoring
- Phenytoin levels monitoring
- Leucovorin concentration increase
- CYP2C9 substrates caution
- Reduced absorption with food
Contraindications
- Severe Renal Impairment
- Hypersensitivity
- Leucopenia
- Neutropenia
- Thrombocytopenia
- Severe reactions to fluoropyrimidine therapy
- Complete DPD deficiency
- Pregnant or breastfeeding
Side Effects
- Abdominal pain
- Rash
- Dry or itchy skin
- Tiredness
- Loss of appetite
- Diarrhea
- Vomiting
- Nausea
- Stomatitis
- Hand-and-foot skin-reaction
- Fever
- Infection
- Chest pain
- Steven-Johnson syndrome
Pregnancy & Lactation
Pregnancy category D. Capecitabine can cause fetal harm. Women are advised of the potential risk to the fetus. Discontinue breastfeeding while receiving treatment and for 2 weeks after the final dose.
Precautions & Warnings
- Coagulopathy: Anticoagulant response monitoring
- Diarrhea: Treatment cessation and antidiarrheal treatments
- Cardiotoxicity: Common in patients with prior coronary artery disease
- Dihydropyrimidine Dehydrogenase Activity: Management based on toxicity
- Dehydration and Renal Failure: Treatment cessation until dehydration correction
- Mucocutaneous and Dermatologic Toxicity: Severe reactions may lead to treatment discontinuation
- Hyperbilirubinemia: Immediate treatment interruption
- Hematologic: Treatment with specific neutrophil and thrombocyte counts
Overdose Effects
Includes nausea, vomiting, diarrhea, mucositis, gastrointestinal irritation and bleeding, and bone marrow depression. Medical management should aim at correcting clinical manifestations and preventing complications.
Therapeutic Class
Cytotoxic Chemotherapy
Storage Conditions
Keep in a dry place below 30°C, protect from light and keep out of the reach of children